Among a range of strategies that have been developed for therapeutically activating p53 in cancer [43], small molecules (e.g., nutlin derivatives) that can bind MDM2 and block its binding to p53 have proven to be effective in elevating the cellular p53 level and inducing apoptosis in various cancer types in clinical trials. This evidence concerns the gene TP53 and cancer.